Cardio3 Biosciences opens US manufacturing facility
European cell therapy specialist Cardio3 BioSciences (Euronext: CARD) is to open a new USA-based manufacturing facility in Rochester, Minnesota.
It will support the company’s current and anticipated manufacturing needs in the USA for the Phase III trial evaluating its lead cell-based cardiovascular product candidate C-Cure. The facility will serve as a base for Cardio3’s research and clinical collaboration with Mayo Clinic, also based in Rochester.
The facility measures 1,000 square meters and is located in the Minnesota Bio Business Center in downtown Rochester. It will initially be used to manufacture C-Cure for use in CHART-2, the US Phase III trial. The company will receive non-dilutive funding from the Minnesota Department of Employment and Economic Development and the Minnesota Job Creation Fund when it completes its investment and hiring goals.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze